Laura Nicholson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Nicholson has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Amitabh C. Pandey
Tulane Research Innovation for Arrhythmia Discovery, Tulane University School of Medicine New Orleans Louisiana USA
3 shared publications Catelyn Anderson
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA
2 shared publicationsChristopher Marsh
Scripps Organ Transplantation Research & Biorepository, Scripps Health, La Jolla, California, USA
2 shared publicationsEmily Spencer
Scripps Research Translational Institute, La Jolla, USA
2 shared publicationsEzra Kurzban
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA
2 shared publications- Jacob New
Bryan Pham, MD, MMSc; Jacob New, MD, PhD; and Dimitrios Tzachanis, MD, PhD, Scripps Health, San Diego, CA
2 shared publications
Latest Publications
- Open Access
Evaluation of an education intervention to support genomics research participation: a community-based pre–post study among participants under-represented in diabetes genomics research
Objective: Develop and study a culturally tailored genomics education tool to better inform future consent processes for genomics research participation among a medically underserved population with diabetes. Design: A single-arm, cohort pre/postsurvey study to assess an educational intervention developed using a community engaged approach. Setting: Federally Qualified Health Centers in San Diego. Participants: Adults (18 years or older) self-identifying as Latino or Hispanic with type 2 diabetes or a history of gestational diabetes were invited to participate. A total of 111 enrolled and completed the preintervention survey; 60 completed the education session and postsurvey. Lay healthcare promotoras previously trained to offer bilingual diabetes education and support were also invited; 34 enrolled and completed the study. Intervention: Using community-engaged research approaches, we developed a genomics education programme to include required elements of informed consent for future diabetes genomics research. The 1-hour, face-to-face genomics education programme was delivered 14 times with a variety of day versus evening and weekday versus weekend options, across a 9-month period. Participants completed a 21-item survey, which included 12 items measuring genomics knowledge and 9 items assessing attitudes towards genomics in healthcare. Primary and secondary outcome measures: Primary outcome was the difference between pre and posteducation mean total genomics knowledge scores among the patients who completed the education session and postsurvey. Secondary outcomes included comparison of baseline survey scores between patient and promotora subgroups, difference between patient pre and posteducation mean total attitude scores, and prescore to postscore changes within each knowledge and attitude survey item. An exploratory analysis of associations between preintervention scores and sociodemographic characteristics was also completed. Results: Among 60 patients, mean genomics knowledge scores significantly increased from 7.3 (SD=1.9) preintervention to 9.4 (SD=1.5) postintervention (ppromotoras (mean 8.1, SD=2.0) had significantly higher knowledge scores than patients (mean 6.9, SD 2.3) (p=0.01). Similarly, promotoras (mean 6.8, SD1.3) demonstrated a more positive attitude than patients (mean 6.0, SD=1.4) (p=0.0008). Patient attitudes towards genomic testing did not change significantly from preintervention to postintervention (6.2 (SD=1.4) vs 6.3 (SD=1.4), p=0.51). Conclusions: A community-informed education intervention improved genomics knowledge in an under-represented population, providing a model to foster more adequately informed consent for advanced technology research participation.
Open AccessEvaluation of an education intervention to support genomics research participation: a community-based pre–post study among participants under-represented in diabetes genomics research
Objective: Develop and study a culturally tailored genomics education tool to better inform future consent processes for genomics research participation among a medically underserved population with diabetes. Design: A single-arm, cohort pre/postsurvey study to assess an educational intervention developed using a community engaged approach. Setting: Federally Qualified Health Centers in San Diego. Participants: Adults (18 years or older) self-identifying as Latino or Hispanic with type 2 diabetes or a history of gestational diabetes were invited to participate. A total of 111 enrolled and completed the preintervention survey; 60 completed the education session and postsurvey. Lay healthcare promotoras previously trained to offer bilingual diabetes education and support were also invited; 34 enrolled and completed the study. Intervention: Using community-engaged research approaches, we developed a genomics education programme to include required elements of informed consent for future diabetes genomics research. The 1-hour, face-to-face genomics education programme was delivered 14 times with a variety of day versus evening and weekday versus weekend options, across a 9-month period. Participants completed a 21-item survey, which included 12 items measuring genomics knowledge and 9 items assessing attitudes towards genomics in healthcare. Primary and secondary outcome measures: Primary outcome was the difference between pre and posteducation mean total genomics knowledge scores among the patients who completed the education session and postsurvey. Secondary outcomes included comparison of baseline survey scores between patient and promotora subgroups, difference between patient pre and posteducation mean total attitude scores, and prescore to postscore changes within each knowledge and attitude survey item. An exploratory analysis of associations between preintervention scores and sociodemographic characteristics was also completed. Results: Among 60 patients, mean genomics knowledge scores significantly increased from 7.3 (SD=1.9) preintervention to 9.4 (SD=1.5) postintervention (ppromotoras (mean 8.1, SD=2.0) had significantly higher knowledge scores than patients (mean 6.9, SD 2.3) (p=0.01). Similarly, promotoras (mean 6.8, SD1.3) demonstrated a more positive attitude than patients (mean 6.0, SD=1.4) (p=0.0008). Patient attitudes towards genomic testing did not change significantly from preintervention to postintervention (6.2 (SD=1.4) vs 6.3 (SD=1.4), p=0.51). Conclusions: A community-informed education intervention improved genomics knowledge in an under-represented population, providing a model to foster more adequately informed consent for advanced technology research participation.
- Open Access
Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
Although immune checkpoint inhibitors (ICIs) have become predominant therapies for cancer, the safety and efficacy of combining ICIs with vaccinations remain areas of needed investigation. As ICIs gain broader clinical application, the relevance of current vaccination guidelines for cancer patients—largely developed in the context of cytotoxic therapies—becomes increasingly uncertain. Although data support the safety of combining inactivated influenza and mRNA SARS-CoV-2 vaccines with ICI therapy, comprehensive data on other infectious disease vaccines remain scarce. Notably, the combination of ICIs with infectious disease vaccines does not appear to exacerbate immune-related adverse events, despite the heightened cytokine activity observed. However, the efficacy of vaccines administered alongside ICIs in preventing infectious diseases remains poorly supported by robust evidence. Preliminary findings suggest a potential survival benefit in cancer patients receiving ICI therapy alongside influenza or SARS-CoV-2 vaccination, though the quality of evidence is currently low. Moreover, the synergistic potential of combining therapeutic cancer vaccines, particularly mRNA-based vaccines, with ICIs indicates promise but with a paucity of phase III data to confirm efficacy. This review critically examines the safety and efficacy of combining ICIs with both infectious disease vaccines and therapeutic cancer vaccines. While vaccination appears safe in patients undergoing ICI therapy, the impact on infectious disease prevention and cancer treatment outcomes warrants further rigorous investigation.
Open AccessImmune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
Although immune checkpoint inhibitors (ICIs) have become predominant therapies for cancer, the safety and efficacy of combining ICIs with vaccinations remain areas of needed investigation. As ICIs gain broader clinical application, the relevance of current vaccination guidelines for cancer patients—largely developed in the context of cytotoxic therapies—becomes increasingly uncertain. Although data support the safety of combining inactivated influenza and mRNA SARS-CoV-2 vaccines with ICI therapy, comprehensive data on other infectious disease vaccines remain scarce. Notably, the combination of ICIs with infectious disease vaccines does not appear to exacerbate immune-related adverse events, despite the heightened cytokine activity observed. However, the efficacy of vaccines administered alongside ICIs in preventing infectious diseases remains poorly supported by robust evidence. Preliminary findings suggest a potential survival benefit in cancer patients receiving ICI therapy alongside influenza or SARS-CoV-2 vaccination, though the quality of evidence is currently low. Moreover, the synergistic potential of combining therapeutic cancer vaccines, particularly mRNA-based vaccines, with ICIs indicates promise but with a paucity of phase III data to confirm efficacy. This review critically examines the safety and efficacy of combining ICIs with both infectious disease vaccines and therapeutic cancer vaccines. While vaccination appears safe in patients undergoing ICI therapy, the impact on infectious disease prevention and cancer treatment outcomes warrants further rigorous investigation.
- Open Access
- 31 January 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (1) , e008233
Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile
Background Despite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this risk to specific medications remains challenging. Methods An observational cohort study from December 11, 2020 to September 22, 2022, within a large healthcare system in San Diego, California, USA was designed to identify medications associated with greatest risk of postimmunization SARS-CoV-2 infection. Adults prescribed WHO Anatomical Therapeutic Chemical (ATC) classified antineoplastic and immunomodulating medications were matched (by age, sex, race, and number of immunizations) with control patients not prescribed these medications yielding a population of 26 724 patients for analysis. From this population, 218 blood samples were collected from an enrolled subset to assess serological response and cytokine profile in relation to immunization. Results Prescription of WHO ATC classified antineoplastic and immunomodulatory agents was associated with elevated postimmunization SARS-CoV-2 infection risk (HR 1.50, 95% CI 1.38 to 1.63). While multiple immunization doses demonstrated a decreased association with postimmunization SARS-CoV-2 infection risk, antineoplastic and immunomodulatory treated patients with four doses remained at heightened risk (HR 1.23, 95% CI 1.06 to 1.43). Risk variation was identified among medication subclasses, with PD-1/PD-L1 inhibiting monoclonal antibodies, calcineurin inhibitors, and CD20 monoclonal antibody inhibitors identified to associate with increased risk of postimmunization SARS-CoV-2 infection. Antineoplastic and immunomodulatory treated patients also displayed a reduced IgG antibody response to SARS-CoV-2 epitopes alongside a unique serum cytokine profile. Conclusions Antineoplastic and immunomodulating medications associate with an elevated risk of postimmunization SARS-CoV-2 infection in a drug-specific manner. This comprehensive, unbiased analysis of all WHO ATC classified antineoplastic and immunomodulating medications identifies medications associated with greatest risk. These findings are crucial in guiding and refining vaccination strategies for patients prescribed these treatments, ensuring optimized protection for this susceptible population in future COVID-19 variant surges and potentially for other RNA immunization targets.
- 31 January 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (1) , e008233
Open AccessEffects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile
Background Despite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this risk to specific medications remains challenging. Methods An observational cohort study from December 11, 2020 to September 22, 2022, within a large healthcare system in San Diego, California, USA was designed to identify medications associated with greatest risk of postimmunization SARS-CoV-2 infection. Adults prescribed WHO Anatomical Therapeutic Chemical (ATC) classified antineoplastic and immunomodulating medications were matched (by age, sex, race, and number of immunizations) with control patients not prescribed these medications yielding a population of 26 724 patients for analysis. From this population, 218 blood samples were collected from an enrolled subset to assess serological response and cytokine profile in relation to immunization. Results Prescription of WHO ATC classified antineoplastic and immunomodulatory agents was associated with elevated postimmunization SARS-CoV-2 infection risk (HR 1.50, 95% CI 1.38 to 1.63). While multiple immunization doses demonstrated a decreased association with postimmunization SARS-CoV-2 infection risk, antineoplastic and immunomodulatory treated patients with four doses remained at heightened risk (HR 1.23, 95% CI 1.06 to 1.43). Risk variation was identified among medication subclasses, with PD-1/PD-L1 inhibiting monoclonal antibodies, calcineurin inhibitors, and CD20 monoclonal antibody inhibitors identified to associate with increased risk of postimmunization SARS-CoV-2 infection. Antineoplastic and immunomodulatory treated patients also displayed a reduced IgG antibody response to SARS-CoV-2 epitopes alongside a unique serum cytokine profile. Conclusions Antineoplastic and immunomodulating medications associate with an elevated risk of postimmunization SARS-CoV-2 infection in a drug-specific manner. This comprehensive, unbiased analysis of all WHO ATC classified antineoplastic and immunomodulating medications identifies medications associated with greatest risk. These findings are crucial in guiding and refining vaccination strategies for patients prescribed these treatments, ensuring optimized protection for this susceptible population in future COVID-19 variant surges and potentially for other RNA immunization targets.
- Open Access
- 15 August 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Regional connectivity drove bidirectional transmission of SARS-CoV-2 in the Middle East during travel restrictions
Regional connectivity and land travel have been identified as important drivers of SARS-CoV-2 transmission. However, the generalizability of this finding is understudied outside of well-sampled, highly connected regions. In this study, we investigated the relative contributions of regional and intercontinental connectivity to the source-sink dynamics of SARS-CoV-2 for Jordan and the Middle East. By integrating genomic, epidemiological and travel data we show that the source of introductions into Jordan was dynamic across 2020, shifting from intercontinental seeding in the early pandemic to more regional seeding for the travel restrictions period. We show that land travel, particularly freight transport, drove introduction risk during the travel restrictions period. High regional connectivity and land travel also drove Jordan’s export risk. Our findings emphasize regional connectedness and land travel as drivers of transmission in the Middle East.
- 15 August 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Open AccessRegional connectivity drove bidirectional transmission of SARS-CoV-2 in the Middle East during travel restrictions
Regional connectivity and land travel have been identified as important drivers of SARS-CoV-2 transmission. However, the generalizability of this finding is understudied outside of well-sampled, highly connected regions. In this study, we investigated the relative contributions of regional and intercontinental connectivity to the source-sink dynamics of SARS-CoV-2 for Jordan and the Middle East. By integrating genomic, epidemiological and travel data we show that the source of introductions into Jordan was dynamic across 2020, shifting from intercontinental seeding in the early pandemic to more regional seeding for the travel restrictions period. We show that land travel, particularly freight transport, drove introduction risk during the travel restrictions period. High regional connectivity and land travel also drove Jordan’s export risk. Our findings emphasize regional connectedness and land travel as drivers of transmission in the Middle East.
- Top Cited PapersOpen Access
- 7 July 2022
- Published by Springer Nature in Nature
- Vol. 609 (7925) , 101-108
Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission
As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing and/or sequencing capacity, which can also introduce biases1–3. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing4,5. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We developed and deployed improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detected emerging variants of concern up to 14 days earlier in wastewater samples, and identified multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.
- 7 July 2022
- Published by Springer Nature in Nature
- Vol. 609 (7925) , 101-108
Top Cited PapersOpen AccessWastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission
As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing and/or sequencing capacity, which can also introduce biases1–3. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing4,5. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We developed and deployed improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detected emerging variants of concern up to 14 days earlier in wastewater samples, and identified multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.
- Open Access
- 18 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266781
6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers
Aim: Healthcare workers (HCWs) were among the first group of people vaccinated with the Pfizer-BioNTech Covid-19 vaccine (BNT162b2). Characterization of the kinetics of antibody response to vaccination is important to devise future vaccination strategies. To better characterize the antibody response to BNT162b2, we analyzed the kinetics of IgG and IgM antibody response to 5 different SARS-CoV-2 epitopes over a period of 6 months. Methods and results: An observational single-centered study was conducted to evaluate the temporal dynamics of anti-SARS-CoV-2 antibodies following immunization with two doses of BNT162b2. Anti-SARS-CoV-2 antibodies were assessed using the Maverick SARS-CoV-2 multi-antigen panel (Genalyte Inc.). Healthcare workers aged ≥18 receiving BNT162b2 vaccination who self-reported no prior symptoms of COVID-19 nor prior COVID-19 PCR test positivity, were included in this study. HCWs developed an IgG antibody response to SARS-CoV-2 Spike S1, Spike S1 receptor binding domain (RBD), Spike S1S2 and Spike S2 after vaccination. IgG response was observed at two weeks following immunization in most participant samples and continued to increase at week 4, but subsequently decreased significantly starting at 3 months and up to 6 months. In contrast, IgM response to respective epitopes was minimal. Conclusion: Multiplex results demonstrate that, contrary to natural infection, immunization with BNT162b2 produces minimal anti-Spike IgM response. Polyclonal IgG response to Spike declined at 3 months and continued to do so up to 6 months.
- 18 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266781
Open Access6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers
Aim: Healthcare workers (HCWs) were among the first group of people vaccinated with the Pfizer-BioNTech Covid-19 vaccine (BNT162b2). Characterization of the kinetics of antibody response to vaccination is important to devise future vaccination strategies. To better characterize the antibody response to BNT162b2, we analyzed the kinetics of IgG and IgM antibody response to 5 different SARS-CoV-2 epitopes over a period of 6 months. Methods and results: An observational single-centered study was conducted to evaluate the temporal dynamics of anti-SARS-CoV-2 antibodies following immunization with two doses of BNT162b2. Anti-SARS-CoV-2 antibodies were assessed using the Maverick SARS-CoV-2 multi-antigen panel (Genalyte Inc.). Healthcare workers aged ≥18 receiving BNT162b2 vaccination who self-reported no prior symptoms of COVID-19 nor prior COVID-19 PCR test positivity, were included in this study. HCWs developed an IgG antibody response to SARS-CoV-2 Spike S1, Spike S1 receptor binding domain (RBD), Spike S1S2 and Spike S2 after vaccination. IgG response was observed at two weeks following immunization in most participant samples and continued to increase at week 4, but subsequently decreased significantly starting at 3 months and up to 6 months. In contrast, IgM response to respective epitopes was minimal. Conclusion: Multiplex results demonstrate that, contrary to natural infection, immunization with BNT162b2 produces minimal anti-Spike IgM response. Polyclonal IgG response to Spike declined at 3 months and continued to do so up to 6 months.
- Open Access
- 1 April 2021
- Published by Elsevier in American Journal of Infection Control
- Vol. 49 (4) , 506-507
Healthcare worker seroconversion for SARS-CoV-2 at two large health systems in San Diego
- 1 April 2021
- Published by Elsevier in American Journal of Infection Control
- Vol. 49 (4) , 506-507
Open AccessHealthcare worker seroconversion for SARS-CoV-2 at two large health systems in San Diego
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e21673
Evaluating financial toxicity (FT) interventions.
E21673 Background: FT has been defined as an adverse event of cancer treatments. Several patient (pt)-level interventions have been developed to mitigate FT. However, due to the lack of longitudinal studies, the impact of these interventions has not been established. Methods: Pts with cancer receiving Co-Pay Assistance (CPA) from the Patient Access Network Foundation were approached at baseline, 1 and 3 months post-CPA. We assessed the use of pt navigators, social workers, financial counselors, support groups, and transportation vouchers by pts. The outcomes were improvements in disease-specific HRQoL measures, global HRQoL measure (FACTG, lower values are worse) and improvement in FT, as measured by the COST (lower values are worse). Multivariable regression was used to identify whether these interventions were associated with the outcomes. Results: 308 pts with cancer were assessed at baseline (prior to CPA) and at 1 and 3 months after. 275 pts (89%) had an improvement in their FT over 3 months. A majority of these pts had multiple myeloma (MM, 86 pts, 28%). Navigators were used by 179 pts (42%), social workers by 106 (34%), financial counselors by 107 (35%), support groups by 94 (31%), and transportation vouchers by 50 (16%). None of these interventions increased the odds of FT or HRQoL improvement at the 0.05 significance level. Conclusions: The selected population of cancer pts who received CPA for their treatments had a significant improvement in FT over time. Yet, this improvement was not associated with additional interventions, suggesting CPA as the main intervention. The FT improvement was not clearly translated into significant HRQoL improvements, likely due to the multidimensional HRQoL construct (which includes other symptoms) versus the unidimensional aspect of a financial event.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e21673
Evaluating financial toxicity (FT) interventions.
E21673 Background: FT has been defined as an adverse event of cancer treatments. Several patient (pt)-level interventions have been developed to mitigate FT. However, due to the lack of longitudinal studies, the impact of these interventions has not been established. Methods: Pts with cancer receiving Co-Pay Assistance (CPA) from the Patient Access Network Foundation were approached at baseline, 1 and 3 months post-CPA. We assessed the use of pt navigators, social workers, financial counselors, support groups, and transportation vouchers by pts. The outcomes were improvements in disease-specific HRQoL measures, global HRQoL measure (FACTG, lower values are worse) and improvement in FT, as measured by the COST (lower values are worse). Multivariable regression was used to identify whether these interventions were associated with the outcomes. Results: 308 pts with cancer were assessed at baseline (prior to CPA) and at 1 and 3 months after. 275 pts (89%) had an improvement in their FT over 3 months. A majority of these pts had multiple myeloma (MM, 86 pts, 28%). Navigators were used by 179 pts (42%), social workers by 106 (34%), financial counselors by 107 (35%), support groups by 94 (31%), and transportation vouchers by 50 (16%). None of these interventions increased the odds of FT or HRQoL improvement at the 0.05 significance level. Conclusions: The selected population of cancer pts who received CPA for their treatments had a significant improvement in FT over time. Yet, this improvement was not associated with additional interventions, suggesting CPA as the main intervention. The FT improvement was not clearly translated into significant HRQoL improvements, likely due to the multidimensional HRQoL construct (which includes other symptoms) versus the unidimensional aspect of a financial event.
- Open Access
- 4 January 2017
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 6 (1) , 3
Liquid Biopsies for Cancer: Coming to a Patient near You
The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis and surveillance of cancer is a rapidly growing area of interest, with sequencing of ctDNA acting as a potential surrogate for tissue biopsy. Circulating tumor DNA has been detected incidentally during noninvasive prenatal testing and additionally in more than 75% of known cancer patients participating in ctDNA studies evaluating its sensitivity. In the setting of mutation-based targeted tumor therapy, it shows a concordance rate >80% when compared with gold-standard tissue biopsies. Through ctDNA detection and sequencing, a simple blood test becomes a liquid biopsy for cancer, surveying a patient’s entire circulation with the goal of early detection, prognostic information, personalized therapy options, and tracking for recurrence or resistance, all with fewer or no tissue biopsies. Given the recent first-ever FDA approval of a liquid biopsy, it is important for clinicians to be aware of the rapid advancements likely to bring these tests into our practices soon. Here we review the biology, clinical implications, and recent advances in circulating tumor DNA analysis.
- 4 January 2017
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 6 (1) , 3
Open AccessLiquid Biopsies for Cancer: Coming to a Patient near You
The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis and surveillance of cancer is a rapidly growing area of interest, with sequencing of ctDNA acting as a potential surrogate for tissue biopsy. Circulating tumor DNA has been detected incidentally during noninvasive prenatal testing and additionally in more than 75% of known cancer patients participating in ctDNA studies evaluating its sensitivity. In the setting of mutation-based targeted tumor therapy, it shows a concordance rate >80% when compared with gold-standard tissue biopsies. Through ctDNA detection and sequencing, a simple blood test becomes a liquid biopsy for cancer, surveying a patient’s entire circulation with the goal of early detection, prognostic information, personalized therapy options, and tracking for recurrence or resistance, all with fewer or no tissue biopsies. Given the recent first-ever FDA approval of a liquid biopsy, it is important for clinicians to be aware of the rapid advancements likely to bring these tests into our practices soon. Here we review the biology, clinical implications, and recent advances in circulating tumor DNA analysis.
- Open Access
- 1 March 2013
- Vol. 4 (1) , 114-117-117
Masquerade without a mass: an unusual cause of severe acute pancreatitis
Masquerade without a mass: an unusual cause of severe acute pancreatitis
- 1 March 2013
- Vol. 4 (1) , 114-117-117
Open AccessMasquerade without a mass: an unusual cause of severe acute pancreatitis
Masquerade without a mass: an unusual cause of severe acute pancreatitis